LLY.US: Incretin leader vs capacity & valuation

Snapshot

Price (approx)

USD 780

Mkt cap (approx)

USD 700.0B

2025 rev (approx)

USD 58.5B

PE (approx)

45

Thesis

Eli Lilly is the core winner of the global obesity/T2D drug cycle via tirzepatide. Capacity, reimbursement, and valuation are the binding constraints.

Business

Model: innovative pharma platform. Flagships: Mounjaro/Zepbound; oncology/immuno base; oral/combo pipeline. Edge: clinical differentiation, capacity investment, commercial reach. 12–24m: supply, oral, outcomes data, payor talks.

Value chain

Downstream commercialization; upstream APIs/devices/fill-finish. Risks: device capacity; cold chain/channel.

Valuation

Premium multiple prices super-blockbuster path; debate is supply vs rivals/payors.

Financial trend (~24 months)

Revenue · last 8Q

Interactive chart available in the reader.

Gross margin · last 8Q

Interactive chart available in the reader.

Operations

Key financials

Key financials

Item	Value	YoY	Note
2025 revenue (approx)	~$58.5B	+30%	Incretin-led
2025 NI (approx)	~$14B+	strong	Margin expand
Key franchise	Mounjaro/Zepbound	—	Obesity/T2D
Capacity CapEx	Elevated	—	Supply ramp

Competition

Peer map

Peer map

Company	Share/role	Margin	Strength	Weakness
Eli Lilly (self)	Obesity leader	~80%+	Tirzepatide + pipeline	Valuation / supply
Novo Nordisk	Semaglutide peer	High	Brand scale	Share fight
Amgen	Pipeline	High	MariTide narrative	Later

Management

Management (24m)

Management (24m)

Role	Name	Since	24m change
CEO	David Ricks	2017-01	No change
CFO	Lucas Montarce	2025	Appointed (transition)
Chair	David Ricks	2017	No change

Stability: steady; watch CFO transition and manufacturing org.

Outlook

Scripts, capacity milestones, rival data, GM, buybacks.

Scenarios

Risks